Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
复制标题
DOI：
10.1093/aje/kwp406
复制
发表时间：
2010-03-01
影响因子：
5
通讯作者：
Thompson, Ian M.
中科院分区：
文献类型：
--
作者：
Schenk, Jeannette M.;Kristal, Alan R.;Thompson, Ian M.
作者使用前列腺癌预防试验（1993-2003）安慰剂组的数据，对血清炎症标志物和症状性良性前列腺增生（BPH）风险进行了巢式病例对照研究。事件性前列腺增生（n = 676）被定义为接受治疗，报告2次国际前列腺症状评分（IPSS）值> - 14，或2次>= 5较基线值增加，且至少1次>= 12。对照组（n = 683）是在7年的试验中未报告BPH治疗或IPSS值为bb70的男性。分析基线血清c反应蛋白、肿瘤坏死因子α（单体）、可溶性肿瘤坏死因子受体I和II （sTNF-RI和sTNF-RII）、白细胞介素6和干扰素γ。对照年龄和种族，高c反应蛋白浓度与BPH风险增加相关(四分位数4 vs四分位数1，优势比（OR) = 1.40, 95%可信区间（CI）： 1.04, 1.88）；在控制体重指数后，这种情况有所减弱（OR = 1.30, 95% CI: 0.95, 1.75）。低sTNF-RII和高白细胞介素6浓度与BPH风险增加相关（四分位数4 vs四分位数1，sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82；白细胞介素6:OR = 1.79, 95% CI: 1.32, 2.42）；这些关联仅在年龄< 65岁的男性中存在。结果表明，全身性炎症或结合炎性细胞因子的可溶性受体水平较低会增加BPH的风险。
The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values > 14, or 2 increases of >= 5 from baseline values with at least one value >= 12. Controls (n = 683) were men who reported no BPH treatment or IPSS values > 7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor alpha (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon gamma. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged < 65 years. Results suggest that systemic inflammation or lower levels of soluble receptors that bind inflammatory cytokines increase BPH risk.